Actively Recruiting
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Led by Vincerx Pharma, Inc. · Updated on 2024-11-15
36
Participants Needed
5
Research Sites
120 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies
CONDITIONS
Official Title
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or myelodysplastic syndrome
- Exhausted all available standard therapies or deemed ineligible for potential available therapies
- At least 5% bone marrow or blood blasts for acute leukemia or myeloblasts for myelodysplastic syndrome
- Evidence of CD123 expression confirmed by local laboratory
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
You will not qualify if you...
- Known central nervous system metastases or carcinomatous meningitis
- Clinically significant cardiac disease including congestive heart failure greater than New York Heart Association Class II
- Unstable angina or new-onset angina within the last 6 months
- Myocardial infarction within the past 6 months before first dose
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233
Actively Recruiting
2
University of Cincinnati
Cincinnati, Ohio, United States, 45219
Actively Recruiting
3
TriStar Bone Marrow Transplant
Nashville, Tennessee, United States, 37203
Actively Recruiting
4
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
5
Fred Hutchinson Cancer Center
Seattle, Washington, United States, 98109
Actively Recruiting
Research Team
V
Vincerx Clinical Trials Contact
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here